Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Celularity Inc. CELU
$0.48
-$0.02 (-4.72%)
На 18:04, 12 мая 2023
+1 150.00%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
68850100.00000000
-
week52high
11.14
-
week52low
0.41
-
Revenue
17975000
-
P/E TTM
-5948
-
Beta
0.20566900
-
EPS
0.08000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Alliance Global Partners | Buy | 25 авг 2022 г. | |
| Truist Securities | Hold | Hold | 23 авг 2022 г. |
| HC Wainwright & Co. | Buy | 22 июн 2022 г. | |
| Truist Securities | Hold | Buy | 06 апр 2022 г. |
| Oppenheimer | Outperform | 28 янв 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 12 сент 2022 г. |
| Oppenheimer | Perform | Outperform | 22 дек 2022 г. |
| Morgan Stanley | Underweight | Equal-Weight | 30 янв 2023 г. |
| HC Wainwright & Co. | Buy | Buy | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hariri Robert J | A | 8074996 | 10000 | 30 ноя 2022 г. |
| Hariri Robert J | A | 8064996 | 40000 | 29 ноя 2022 г. |
| Hariri Robert J | A | 8024996 | 40000 | 28 ноя 2022 г. |
| Fletcher Kyle | D | 34170 | 1262 | 16 ноя 2022 г. |
| Jones Anne | D | 49154 | 3734 | 16 ноя 2022 г. |
| Kilcoyne Adrian | A | 66226 | 66226 | 03 окт 2022 г. |
| SCULLEY JOHN | D | 0 | 768594 | 26 авг 2022 г. |
| SCULLEY JOHN | A | 804739 | 768594 | 26 авг 2022 г. |
| Hariri Robert J | D | 230287 | 119073 | 24 авг 2022 г. |
| Hariri Robert J | A | 7984996 | 119073 | 24 авг 2022 г. |
Новостная лента
Celularity, Inc. (CELU) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research
24 янв 2023 г. в 10:32
Zacks.com users have recently been watching Celularity, Inc. (CELU) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors Heavily Search Celularity, Inc. (CELU): Here is What You Need to Know
Zacks Investment Research
11 янв 2023 г. в 10:32
Zacks.com users have recently been watching Celularity, Inc. (CELU) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
After Plunging -38.63% in 4 Weeks, Here's Why the Trend Might Reverse for Celularity, Inc. (CELU)
Zacks Investment Research
09 янв 2023 г. в 11:17
Celularity, Inc. (CELU) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ACER Down Despite FDA Nod for Urea Cycle Disorders Drug
Zacks Investment Research
28 дек 2022 г. в 10:51
The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Celularity, Inc. (CELU)
Zacks Investment Research
23 дек 2022 г. в 11:17
Celularity, Inc. (CELU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.